FDA perspective on the dsm-5 approach to classification of "cognitive" disorders

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 2, 2011, Pages 126-131

  Laughren, Thomas ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

AGGRESSION; ALZHEIMER DISEASE; AMNESIA; ANGER; ANXIETY; APATHY; ARTICLE; BEHAVIOR DISORDER; CAREGIVER BURDEN; CLINICAL FEATURE; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 5; DRUG APPROVAL; DRUG CONTROL; EATING DISORDER; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SLEEP DISORDER; STEREOTYPY; SUICIDAL IDEATION; WANDERING BEHAVIOR; CLASSIFICATION; UNITED STATES;

ALZHEIMER DISEASE; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85047687726     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/jnp.23.2.jnp126     Document Type: Article

References (13)

1. http://dsm5.org/pp/Default.aspx
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, D.C, American Psychiatric Association, 2000
3. Paulsen JS, Ready RE, Stout JE, et al: Neurobehaviors and psychotic symptoms in Alzheimer's disease. J Int Neuropsychol Soc 2000; 6:815-820
4. Heinrichs RW, Zakzanis KK: Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsycholog 1998; 12:426-445
5. Green MF: What are the functional consequencesof neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330
6. http://www.matrics.ucla.edu
7. http://www.ipa-online.orgipaonlinev3/ipaprograms/taskforces/bpsd/intro.asp
8. http://www.fda.gov/ohrms/dockets/ac/cder00.htm#Psychopharmacologic
9. Finkel SI, Burns A, Cohen G: Overview, in Behavioral and psychological symptoms of dementia (BPSD): a clinical and research update. Int J Psychogeriatr 2000; 12(suppl1):13-18
10. Laughren TP: A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am J Geriatr Psychiatry 2001; 9:340-345
11. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafet InformationforPatientsandProviders/ucm124830.htm
12. Buchanan HW, Davis M, Goff D, et al: A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr Bull 2005; 31:1-15
13. Mitchell AJ, Shiri-Feshki M: Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119:252-265